3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Unknown
1
Recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Prostatic Neoplasms
54
Breast Neoplasms
43
Neoplasms
4
Salivary Gland Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostate Adenocarcinoma
2
Advanced Breast Cancer
2
Recurrence
1
PSA Level Greater Than Two
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Lymphatic Metastasis
1
Inflammatory Breast Neoplasms
1
Hormone-sensitive Metastatic Breast Cancer
1
Hormone Sensitive Prostate Cancer
1
Hodgkin Disease
1
Hereditary Sensory and Autonomic Neuropathies
1
HER2-positive Breast Cancer
1
HER2 Negative Breast Cancer
1
Fallopian Tube Neoplasms
1
Castrate Sensitive Prostate Cancer
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Lobular
1
Bulbo-Spinal Atrophy, X-Linked
1
Breast Neoplasms, Male
1
Anatomic Stage I Breast Cancer AJCC v8
1
Interventions
Carboplatin
79
pembrolizumab
64
Paclitaxel
64
Cyclophosphamide
47
Capecitabine
34
Doxorubicin
31
Taxes
28
130-nm albumin-bound paclitaxel
28
Albumin-Bound Paclitaxel
27
Gemcitabine
20
atezolizumab
18
Epirubicin
18
Cisplatin
18
Bevacizumab
18
olaparib
17
sacituzumab govitecan
15
Docetaxel
15
eribulin
14
toripalimab
13
durvalumab
13
camrelizumab
13
Drug Therapy
12
apatinib
9
Trastuzumab
9
Radiotherapy
9
Specimen Handling
8
Magnetic Resonance Spectroscopy
8
Biopsy
8
tislelizumab
7
talazoparib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
Triple Negative Breast Neoplasms
×
Goserelin
×
Clear all
NCT05582499
2026-05-28
FASCINATE-N
Fudan University
Phase 2
Recruiting
716 enrolled
NCT03444025
2018-02-23
NeoGONT
Kasr El Aini Hospital
Phase 2
Unknown
180 enrolled